---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-001119"
form_type: "8-K"
ticker: "UG"
cik: "0000101295"
company_name: "UNITED GUARDIAN INC"
filed_at: "2024-03-01T23:59:59+00:00"
generated_at: "2026-06-05T05:14:25.025311+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "medium"
source: SEC EDGAR
---

# United-Guardian entered into manufacturing & supply agreement with Amsino for Renacidin Irrigation

## Summary
- Agreement with Amsino Healthcare (USA) effective Jan 1, 2023 for manufacture and supply of Renacidin Irrigation.
- Initial term of 6 years with automatic renewal for two successive 2-year periods.
- Company will supply raw materials; Amsino manufactures, tests, releases, and ships product.
- Customary provisions for regulatory compliance, quality control, indemnification, confidentiality.

## SEC filing metadata
- accession: 0001171843-24-001119
- form_type: 8-K
- ticker: UG
- cik: 0000101295
- company_name: UNITED GUARDIAN INC
- filed_at: 2024-03-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: medium
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/101295/000117184324001119/0001171843-24-001119-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/101295/000117184324001119/f8k_022924.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-001119
- JSON: https://secwatch.observer/filing/0001171843-24-001119.json
- Plain text: https://secwatch.observer/filing/0001171843-24-001119.txt

## Key facts
- Material Agreements
  UNITED GUARDIAN INC entered into Manufacturing and Supply Agreement with Amsino Healthcare (USA), Inc. (effective 2023-03-30).
  - Action: entry
  - Agreement: supply
  - Counterparty: Amsino Healthcare (USA), Inc.
  - Effective: 2023-03-30
  source text: On March 30, 2023, United-Guardian, Inc. (the “Company”) entered into a manufacturing and supply agreement with Amsino Healthcare (USA), Inc. (“Amsino”), the successor in interest to Smiths Medical, effective as of January 1, 2023 (the “Agreement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/101295/000117184324001119/0001171843-24-001119-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.